CRISPR Therapeutics begins natural killer cell cancer tie-up with Nkarta
pharmaphorum
MAY 7, 2021
Gene editing firm CRISPR Therapeutics has announced a collaboration with US biotech Nkarta to develop natural killer (NK) cell therapies for cancer. It’s at the forefront of gene editing although the technology has spawned rivals including Intellia Therapeutics, Caribou Biosciences, Sangamo Therapeutics and Mammoth Biosciences.
Let's personalize your content